As biotechnology rapidly becomes one of the most strategic sectors in global science and innovation, China has emerged not just as a participant but a potential frontrunner. From pioneering gene-editing therapies to challenging the dominance of Western pharma giants, China’s biotech ascent reflects more than just scientific ambition—it signals a recalibration of global technological power. For countries like India, the window to catch up is narrowing.
Biotech has long been framed by dual narratives: a promise of transformative healthcare solutions and a cautionary tale of bioethics and geopolitical risk. China, more than any other nation, embodies this paradox. Global scrutiny intensified following controversies like the CRISPR-edited embryo scandal, the opaque origins of COVID-19, and heightened fears over synthetic biology misuse. These incidents shaped narratives that continue to influence Western policy responses, most notably the U.S. Biosecure Act, which restricts federal funding to firms with ties to specific Chinese biotech entities like BGI Group.
But framing China solely through a biosecurity lens misses a much larger story: its strategic transformation into a biotech innovation powerhouse.
China’s Deep Tech Awakening
China’s biotech sector is no longer synonymous with generic drug manufacturing or reverse-engineering Western patents. It is now producing cutting-edge therapies with global implications. Consider Huida Gene Therapeutics, which developed the world’s first CRISPR-Cas13 RNA editing-based therapy for age-related macular degeneration. Or Akeso’s Ivonescimab, an immunotherapy drug that recently outperformed Merck’s Keytruda in Phase III trials. And in a milestone for AI-driven drug discovery, Insilico Medicine’s generative AI-discovered drug Rentosertib entered Phase II trials—tested and developed in China.
What makes these achievements possible? A well-integrated ecosystem linking academia, government, and industry. China’s biotech rise is built on decades of calculated policy moves. It began with Deng Xiaoping’s reform era and gained momentum through landmark programs like the 863 Plan, which laid the foundation for biotech infrastructure and foreign collaboration in science parks such as Shenzhen.
From Policy Blueprint to Global Contender
Over time, fragmented policy frameworks evolved into a national innovation strategy. The “Made in China 2025” plan placed biotech at the heart of manufacturing transformation. “Healthy China 2030” integrated biotech into public health priorities, while fast-track regulatory pathways were introduced to streamline drug approvals.
Perhaps the most transformative factor has been talent. Through ambitious brain gain programs, China reversed the traditional flow of talent migration. It actively recruited foreign-trained scientists back home, helping reform research culture and raise the quality of biotech outputs. DeepSeek, China’s breakthrough in large language model AI, is just one example of homegrown talent producing globally disruptive technologies. That same logic is now unfolding in biotech.
In March 2025, Beijing announced a ¥1 trillion national venture capital guidance fund—a public-private partnership to fuel disruptive technologies including biotech and AI. This was reinforced at the annual “Two Sessions,” where China’s new development model placed innovation, particularly in life sciences, at the center of its strategy to achieve “new quality productive forces.”
The Innovation Gap: Lessons for India
While India’s biotech sector has shown remarkable growth—from $10 billion in 2015 to $130 billion in 2024—it still trails China in innovation and global competitiveness. India’s strengths lie in affordability and scale: NexCAR9, the world’s most affordable cancer immunotherapy, and the country’s first gene-edited rice are major accomplishments. Yet when it comes to frontier R&D and commercialization, India faces barriers.
India spends only 0.7% of GDP on R&D compared to China’s 2.6%. Regulatory fragmentation, limited venture capital in deep biotech, and weak academia-industry linkages continue to slow progress. While new policy initiatives like BioE3 and Bio-RIDE are promising, they require rapid operationalization and robust institutional backing.
India must also leverage recent geopolitical shifts—like tighter U.S. immigration rules—to reverse its own brain drain. If China could repatriate talent and become a biotech superpower, so can India.
Biotech’s Strategic Stakes
The future of biotech isn’t just about curing disease—it’s about power. Biotech sits at the intersection of national security, economic sovereignty, and global influence. China’s trajectory shows what long-term strategy, investment, and talent development can yield.
India must now decide whether to treat biotech as another sunrise sector—or as the strategic lever it truly is.
Because in this unfolding era of tech decoupling and innovation races, biotech’s “DeepSeek moment” may only come once.
What an insightful exploration of China’s biotech journey! It’s fascinating to see how strategic investment and talent repatriation are reshaping the landscape. India has a lot to learn from this playbook!